Let's Help Each Other
Patient Response to Immunotherapy using Spliceosome Mutational Markers or PRISMM is a Johns Hopkins trial for patients with advanced breast cancer whose tumors have been sequenced and have a spliceosome mutation (SF3B1). Your participation may help you – while you help us study and treat cancers with rare mutations. This trial is registered at clinicaltrials.gov (NCT04447651).
PRISMM is a novel trial offered through Johns Hopkins, designed for patients with advanced breast cancers whose tumors have been sequenced and carry a specific rare mutation (SF3B1)
Help transform how cancer research works. Collaborate with us in this novel trial.
Fill out our secure online intake survey and enroll in PRISMM today.
PI: Cesar Augusto Santa-Maria, MD MSCI